When examining a set of direct p53 target genes that contain validated p53 binding sites [32] and that are differentially expressed between p53+/+ and p53–/– AML, their median expression is reduced in E177R AML by 47.1% (Fig. 5D and E). This evidence concerns the gene TP53 and acute myeloid leukemia.